Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 140 No. 2728 (2010)

Metabolic control of type 1 diabetic patients followed at the University Children’s Hospital in Bern: Have we reached the goal?

  • P Tonella
  • C Flück
  • P Mullis
DOI
https://doi.org/10.4414/smw.2010.13057
Cite this as:
Swiss Med Wkly. 2010;140:w13057
Published
05.07.2010

Summary

Question under study: In type 1 diabetes (T1DM), a good metabolic control is important to reduce and/or postpone complications. Guidelines regarding how to achieve this goal are published by the American Diabetes Association (ADA) and the International Society of Paediatric and Adolescence Diabetes (ISPAD). The aims of this study were to determine the current level of metabolic control in T1DM patients on different treatment regimens, followed at the diabetes outpatient unit of the University Children’s Hospital Bern, Switzerland, and to compare it with both the reported data from ten years ago (1998) and with the current guidelines of the ADA and ISPAD.

Methods: This was an observational, cross-sectional study and involved assessment of HbA1c levels as a surrogate marker of the metabolic control in all patients seen during a regular four month interval at our outpatient clinic.

Results: A total of 152 patients (88m, 64f) were recorded. 43.4% (n = 66) were conventionally treated (insulin: twice-daily, three-dose treatment), whereas 56.6% (n = 86) were on a multiple injection treatment (e.g. functional insulin treatment and/or insulin pump). Actual overall HbA1c values, expressed as medians (25th/75thcentiles), were 7.6% (7.0/8.3) compared to 7.9% (7.3/8.6) in 1998 (p <0.01). In younger, prepubertal children the HbA1c value recorded was 7.4% (6.9/8.1), and 7.7% (7.2/8.5) in adolescents. Interestingly, no significant difference was observed between HbA1c levels of conventionally versus intensively treated patients.

Conclusions: With current treatment strategies, glycaemic control of T1DM children and adolescents improved significantly (p <0.01) between 1998 and 2008, although only a minority of the subjects reached the ISPAD goals.

References

  1. Vandewalle CL, Coeckelberghs MI, De Leeuw IH, Du Caju MW, Schuit FC, Pipeleers DG et al. Epidemiology, clinical aspects, and biology of IDDM patients under the age of 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry. Diabetes Care. 1997;20:1556–61.
  2. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027–33.
  3. Schoenle EJ, Lang-Muritano M, Gschwend S, Laimbacher J, Mullis PE, Torresani T, et al. Epidemiology of Type I diabetes mellitus in Switzerland: step rise in incidence in under 5 year old children in the past decade. Diabetologia. 2001;44:286–9.
  4. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
  5. DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125:177–88.
  6. DCCT/EDIC Writing Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Development and Complications (EDIC) study. JAMA. 2003;290:2159–67.
  7. Nathan DM, Cleary PA, Backlund JY Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
  8. Allemann S, Saner C, Zwahlen M, Christ ER, Diem P, Stettler C. Long-term cardiovascular and non-cardiovascular mortality in women and men with type 1 and type 2 diabetes mellitus: a 30-year follow-up in Switzerland. Swiss Med Wkly. 2009;139(39-40):576–83.
  9. Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complications – the Linköping Diabetes Complications Study. Pediatr Diabetes. 2009;10(3):168–76.
  10. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with microvascular and macrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
  11. American Diabetes Association. Standards of Medical Care in Diabetes 2009. Diabetes Care. 2009;32:Suppl 1.
  12. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, et al. American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care. 2005;28(1):186–212.
  13. Donaghue K, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K. ISPAD Clinical Practice Consensus Guidelines 2009. Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes. 2009;10(Suppl 12):195–203.
  14. Flück CE, Kuhlmann BV, Mullis PE. Metabolic control in children and adolescents with diabetes mellitus type I in Berne: a cross-sectional study. Schweiz Med Wochenschr. 1999;129(44):1650–5.
  15. Cole TJ, Bellizzi MC, Flegal KM, Dietz W. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000;320(7244):1240–3.
  16. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976;51(3):170–9.
  17. Mortensen HB, Robertson KJ, Aanstoot HJ, Danne T, Holl RW, Hougaard P et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidøre Study Group on Childhood Diabetes. Diabet Med. 1998;15(9):752–9.
  18. Danne T, Mortensen HB, Hougaard P, Lynggaard H, Aanstoot HJ, Chiarelli F et al. for the Hvidøre Study Group on Childhood Diabetes. Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidøre Study Group. Diabetes Care. 2001;24(8):1342–7.
  19. De Beaufort CE, Swift PG, Skinner CT, Aanstoot HJ, Aman J, Cameron F et al. Continuing Stability of Center Differences in Pediatric Diabetes Care: Do Advances in Diabetes Treatment Improve Outcome? The Hvidøre Study Group on Childhood Diabetes. Diabetes Care. 2007;30(9):2245–50.
  20. Lombardo F, Valenzise M, Wasniewska M, Messina MF, Ruggeri C, Arrigo T, et al. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab. 2002;15(4):246–51.
  21. Böber B, Dündar B, Büyükgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab. 2001;14(4):435–41.
  22. Bovet P, Chiolero A, Paccaud F. Epidemiology and prevention of obesity in children and adolescents. Rev Med Suisse. 2008;4(148):650–2, 654–6.
  23. Guerci B, Benichou M, Floriot M, Bohme P, Fougnot S, Franck P, et al. Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients. Diabetes Care. 2003;26(4):1137–41
  24. Acerini CL, Cheetham TD, Edge JA, Dunger DB. Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. Diabetologia. 2000;43:61–8.
  25. Dunger DB, Edge JA. Diabetes and endocrine changes of puberty. Pract Diab Internat. 1995;12:63–6.
  26. Du Pasquier-Fediaevsky L, Chwalow AJ, Tubiana-Rufi N. Is the relationship between adherence behaviours and glycaemic control bi-directional at adolescence? A longitudinal cohort study. Diabet Med. 2005;22(4):427–33.
  27. Hood KK, Peterson CM, Rohan JM, Drotar D. Association Between Adherence and Glycemic Control in Pediatric Type 1 Diabetes: A Meta-Analysis. Pediatrics. 2009;124;1171–9.
  28. Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klingensmith G, et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr. 2003;143:737–40.
  29. Murphy NP, Keane HN, Ong KK, Ford-Adams M, Edge JA, Acerini CL, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care. 2003;26:799–804.